Trevi Therapeutics, Inc. (TRVI)
| Market Cap | 2.02B +286.9% |
| Revenue (ttm) | n/a |
| Net Income | -42.76M |
| EPS | -0.32 |
| Shares Out | 140.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 970,262 |
| Open | 14.00 |
| Previous Close | 14.19 |
| Day's Range | 14.00 - 14.46 |
| 52-Week Range | 5.38 - 16.12 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 21.55 (+49.55%) |
| Earnings Date | May 8, 2026 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price target is $21.55, which is an increase of 49.55% from the latest price.
News
Trevi Therapeutics to Participate in Upcoming May Events
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphi...
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
What's Going On With Trevi Therapeutics Stock?
Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares are trading higher after the company announced the pricing of its $150 million offering of 11.6 million shares at $13 per share.
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics to Participate in Upcoming Events
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics Earnings Call Transcript: Q4 2025
Major growth in 2025 was driven by positive clinical data and a clear FDA path for pivotal trials in chronic cough. With $188M in cash, the company is positioned to fund key trials into 2028 and expand into larger markets with high unmet need.
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough
Trevi Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Strong Phase II results in chronic cough have set the stage for two pivotal Phase III trials, with FDA alignment on endpoints and timelines targeting NDA filing in about two and a half years. Expansion into non-IPF ILD and RCC, differentiated mechanism, and robust financial runway position the program for significant commercial impact.
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
T he Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough
Trevi Therapeutics to Participate in Upcoming March Conferences
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Statistically-s ignificant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant...
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patients with idiopathic pulmonary fibrosis Phase 2b refractory chronic cough trial pla...
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn. , Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clini...
Trevi Therapeutics Earnings Call Transcript: Q3 2025
Positive clinical data and a $115M capital raise have extended cash runway into 2028, supporting multiple late-stage trials in chronic cough indications. Q3 net loss narrowed to $11.8M, with strong investigator interest and regulatory alignment underway.
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 m...
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idio...
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
NEW HAVEN, Conn. , Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine E...
Trevi Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A single-asset company is advancing a mixed agonist-antagonist opioid drug for chronic cough in IPF, non-IPF ILDs, and RCC, with strong phase 2 data and a specialty-focused commercial strategy. Patent protection extends to 2039, and over $200 million in cash supports trials through 2028. FDA engagement and AI-driven operations are key priorities.
Trevi Therapeutics Transcript: Cantor Global Healthcare Conference 2025
The company is advancing STAT3 inhibitors for IPF and oncology, with a pivotal IPF data readout expected in Q4 and HCC data in H1 2026. Interim trial results show promising lung function stabilization, and a next-generation prodrug is in development for improved delivery.
Trevi Therapeutics to Participate in Upcoming September Conferences
NEW HAVEN, Conn. , Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...